KDR and cancer: The goal of our work is to synthesise new tolmetin derivatives with the same essential pharmacophoric features of the reported and clinically used sunitinib (through molecular hybridisation with the essential moieties of PAC-1, sorafenib or cyclisation of N,N-diethylamine moiety of sunitinib, highlighted in Figure 2), aiming the development of efficient anticancer agents that exhibited different enzymatic and cellular targets such as apoptosis induction in different human cancer cell lines and inhibition of VEGFR-2.